HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The Netherlands Working Group on Cardiovascular Research (WCN).

Abstract
The gastrointestinal therapeutic system formulation of nifedipine enables a once-daily dosing resulting in predictable, relatively constant plasma concentrations. To evaluate the efficacy and safety of this formulation and to compare this with the beta-blocker atenolol, we conducted a double-blind, randomised, multi-centre study in 129 male patients with documented exercise induced angina pectoris. After 4 weeks' treatment, nifedipine (60 mg), improved time to onset of 0.1 mV ST-segment depression from 536 s by 72 +/- 117s, time to onset of pain from 619 s by 56 +/- 120 s, and total exercise time from 685 s by 40 +/- 88 s. Atenolol 100 mg, had a comparable effect, time to onset of 0.1 mV ST-segment depression improved from 496 s by 53 +/- 129 s, time to onset of pain from 572 s by 57 +/- 118 s, and total exercise time from 653 s by 33 +/- 99 s. Between group analysis revealed no statistically significant differences for these exercise parameters. Atenolol, but not nifedipine, significantly reduced heart rate and systolic blood pressure at rest and during exercise (P < 0.001 between groups), indicating different modes of action of the drugs. With regard to safety, both drugs were generally well tolerated. There were significantly (P = 0.01) more vasodilation related side effects with nifedipine. These data demonstrate that gastrointestinal therapeutic system formulation of nifedipine and atenolol as once-daily monotherapy are equally effective and safe, but with different effects on exercise parameters.
AuthorsR J de Vries, A F van den Heuvel, D J Lok, R J Claessens, P J Bernink, W H Pasteuning, J H Kingma, P H Dunselman
JournalInternational journal of cardiology (Int J Cardiol) Vol. 57 Issue 2 Pg. 143-50 (Dec 6 1996) ISSN: 0167-5273 [Print] IRELAND
PMID9013266 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic beta-Antagonists
  • Vasodilator Agents
  • Atenolol
  • Nitroglycerin
  • Nifedipine
Topics
  • Administration, Oral
  • Adrenergic beta-Antagonists (administration & dosage, therapeutic use)
  • Aged
  • Angina Pectoris (diagnosis, drug therapy, physiopathology)
  • Atenolol (administration & dosage, therapeutic use)
  • Double-Blind Method
  • Drug Administration Schedule
  • Electrocardiography
  • Exercise Test
  • Exercise Tolerance (drug effects)
  • Humans
  • Male
  • Middle Aged
  • Nifedipine (administration & dosage, adverse effects)
  • Nitroglycerin (administration & dosage)
  • Treatment Outcome
  • Vasodilator Agents (administration & dosage, adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: